> Contact us

Watch video

IMPLEMENTING REAL-TIME MONITORING AND MAKING IT A SUCCESS STORY

There are several success stories on how real-time monitoring has saved high value products and ensured drug availability. However, Niclas Ohlsson, CEO at TSS, believes companies need to carefully assess and plan before deciding to implement real-time monitoring in their life science supply chains.

Scroll to read on 

I

In the TSS real-time application you can follow your most valuable shipments live, all the way to the last mile. Although this type of application opens up for huge possibilities, it is important to remember that it also requires companies to think through how the organisation and its processes are affected.


This typically calls for an escalation process as well as an organization that is available 24/7, with a global operation team that can, if needed, interact and initiate corrective actions. In the complex eco system of a supply chain, that may involve different companies, experts need to be accessible and actionable.

The first impact of implementing real-time monitoring is the need for a control tower. This control tower must be able to capture all alarms, to be qualified to interpret them, and to conclude what action is suitable, and by whom

Before deciding to implement real-time monitoring, you need to ask yourself: is there a risk that we turn our organization into a reactive rather than a proactive organization? And what is the cost for that?

Niclas Ohlsson says, that, in order to assess the possible effectiveness of real-time monitoring, the supply chain’s white and dark spaces need to be identified. Depending on how your supply chain has been set up, it is important to map areas where possible actions can be taken, but also where it can not be. This information should be mapped against historical data where issues are typically initiated or escalating.


“If there is a high positive overlap, the analysis should assess the causes for the deviation. Knowing this, you need to assess how such a situation can be addressed in the field - which action is required?”


The percentage of cases that could be addressed, and the cost for these real time actions, should then be compared with a proactive action that could alternatively resolve the issue.

To make sure your real-time monitoring experience becomes a success stories, it is crucial that you know which questions to ask during the evaluation process, and what to expect from the vendor. 

> Download TSS’ buyer’s guide to real-time temperature monitoring to learn more!

Go to article: Home | The dengue dilemma Go to article: In this issueGo to article: Owen MumfordGo to article: ContentsGo to article: Hapa Company Insight Go to article: Daiichi JitsugyoGo to article: NewsGo to article: EmbocapsGo to article: HOF Sonderanlagenbau Company Insight Go to article: HOF SonderanlagenbauGo to article: The pharma industry briefingGo to article: Dow Europe Company InsightGo to article: Gerteis Company InsightGo to article: GerteisGo to article: The problem of manipulated data Go to article: Capsugel Company Insight Go to article: CapsugelGo to article: Timeline: the dengue vaccine dilemmaGo to article: TSS Company Insight Go to article: TSSGo to article: From evergreening to thicketing: exploring manipulation of the pharma patent sysGo to article: Emirates SkyCargoGo to article: AtoZ-CRO Company InsightGo to article: AtoZ-CROGo to article: A safer ride: the latest innovation in targeted cancer treatment Go to article: Swiss WorldCargoGo to article: Accurate BiometricsGo to article: Accurate Biometrics Company Insight Go to article: Nelson LabsGo to article: Treading the line: the challenge of transplant rejection drugsGo to article: Corbion PuracGo to article: Erdmann Design Company InsightGo to article: Erdmann Design SwitzerlandGo to article: Treating menopause: at last a non-hormonal alternative? Go to article: YourwayGo to article: ImmuMap Company Insight Go to article: ImmuMapGo to article: Drug repurposing: the industry’s all-rounder medicinesGo to article: FargoGo to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: One step closer to a Chlamydia vaccine Go to article: AralabGo to article: Synex SyntheticsGo to article: Deals in brief powered by GlobalDataGo to article: Charles Ischi Go to article: The key list powered by GlobalDataGo to article: Pharmaceutical Solutions IndustryGo to article: Clinichain Company Insight Go to article: ClinichainGo to article: SanofiGo to article: EventsGo to article: NymiGo to article: Modality SolutionsGo to article: PfanstiehlGo to article: Next issueGo to article: MimotopesGo to article: ICCI - International Cannabis and Cannabinoids Institute Go to article: ICCI